{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/breast-cancer-managing-fh/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"f7449f3e-937f-584a-90af-48470e794a2c","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 0a46a712-21a2-428d-91c8-05e9b324087b --><h2>Changes</h2><!-- end field 0a46a712-21a2-428d-91c8-05e9b324087b -->","summary":null,"htmlStringContent":"<!-- begin item a85f7c14-94d9-422e-a8c9-e7958e117ecd --><!-- begin field adc04b95-aa1b-49bc-afee-8e86021ce535 --><p><strong>December 2018 </strong>— reviewed. A literature search was conducted in December 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to clinical recommendations have been made.</p><!-- end field adc04b95-aa1b-49bc-afee-8e86021ce535 --><!-- end item a85f7c14-94d9-422e-a8c9-e7958e117ecd -->","topic":{"id":"273ad47e-ae65-5768-be53-5ddd1a59479e","topicId":"bd5ef0a7-5bdf-453b-919f-23ebeade59e8","topicName":"Breast cancer - managing FH","slug":"breast-cancer-managing-fh","lastRevised":"Last revised in December 2018","chapters":[{"id":"f6ca27fc-9049-5932-b6b5-c6a1a14a77fd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2dd4a7a9-b879-5145-a15c-5922ac8e62ed","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1eedf81f-6c36-5c24-816f-0c373b4fe0f4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f7449f3e-937f-584a-90af-48470e794a2c","slug":"changes","fullItemName":"Changes"},{"id":"28bea84b-3026-59d1-a564-3b8f8e660f19","slug":"update","fullItemName":"Update"}]},{"id":"d2268871-af9e-569e-ae6e-a786ab1bacec","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c2ad0bbf-95fa-5512-a763-618d653b1f5e","slug":"goals","fullItemName":"Goals"},{"id":"b4ec1615-f118-573f-a98d-d4bbfdf7d53d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"467c7316-a736-5600-b8e5-1c4ebf44b7ce","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"34c8a1ea-20f5-5197-86ff-6e75ed2a01c5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3361517e-9866-5a17-aabf-4d923a96c917","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"fdcd7c54-3a68-5903-a4a1-241a63d19e62","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d7bd1803-d45e-508d-8661-62ebaa4b3353","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6831679-919f-5e59-b6b9-d09ed6486aca","slug":"definition","fullItemName":"Definition"},{"id":"7d6fa54b-1dc8-5cbd-9bf4-6d9ac0dc26f0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c5d1b518-b87d-58d6-8554-f3960af8f976","slug":"genetic-risk-factors","fullItemName":"Genetic risk factors"}]},{"id":"61970169-7827-5d9e-acb0-e40e0888525d","fullItemName":"Management","slug":"management","subChapters":[{"id":"b118c829-c5a1-5ee5-a8da-71eb67facd8d","slug":"breast-cancer-managing-fh","fullItemName":"Scenario: Breast cancer - managing FH"}]},{"id":"eaf7a93e-8dae-5737-ba9c-13e8ad484b3c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a9d84940-3c17-5039-b3f8-73ef73f06d13","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a8dea3b7-f328-50ea-985f-2d54f906032c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"067fe34b-66c2-52be-b2a6-f9366eaa8c2e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1f91e5ff-a2aa-5aaf-ac5c-67750822d1e8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0bfaeb6f-e800-5a87-a861-0d00aeb7c136","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"773a3929-781a-5faf-8d55-166112725d3a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"89bfc412-56d8-52c5-95b1-6e923396679a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1eedf81f-6c36-5c24-816f-0c373b4fe0f4","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"52c1fe6a-dc4b-5e82-85eb-bbbb6000c4df","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field feffa568-3252-4e68-8040-8feb0fa64300 --><h3>Previous changes</h3><!-- end field feffa568-3252-4e68-8040-8feb0fa64300 -->","summary":null,"htmlStringContent":"<!-- begin item 571169e5-1699-4d50-a65a-1090e15676e7 --><!-- begin field 83eb9654-5860-4524-9ab5-be85e8210061 --><p><strong>December 2013 </strong>— reviewed. A literature search was conducted in August 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. Recommendations on who to refer have been changed to reflect the most recent guidance from the National Institute for Health and Care Excellence (2013).</p><p><strong>June 2012 </strong>— minor update. Recommendation and basis reworded in the <em>Advice on hormonal contraception </em>node to clarify that women with a family history of breast cancer can use any combined hormonal contraceptive (CHC), not just combined oral contraceptives (COC). Also, in women who are known carriers of a gene mutation, all CHCs (not just COCs) should be avoided.</p><p><strong>September 2011 </strong>— minor update. Information added about the roll out of the NHS breast screening programme across England to include women aged 47 to 49 years and women aged 71 to 73 years. Issued November 2011.</p><p><strong>November 2009 </strong>— correction to age range in <em>Advice on risk reduction</em>. Issued in November 2009.</p><p><strong>July to November 2009</strong> — converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>September 2008 </strong>— minor correction to the <em>Changes </em>section. Issued in September 2008.</p><p><strong>May 2007 </strong>— updated. The new advice on magnetic resonance imaging (MRI) for breast cancer screening from the recent update of the NICE guideline on <em>Familial breast cancer </em>has been included. Issued in May 2007.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>August 2004 </strong>— written. Validated in November 2004 and issued in February 2005.</p><!-- end field 83eb9654-5860-4524-9ab5-be85e8210061 --><!-- end item 571169e5-1699-4d50-a65a-1090e15676e7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}